EGFR Mutant NSCLC Post Osimertinib

Episode
152
Soundcloud
Share

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a new Virtual Tumor Board on EGFR mutant NSCLC and acquired resistance. Dr. Liu is joined by two thoracic medical oncologists, Dr. Xiuning Le and Dr. Hidehito Horinouchi, both global experts in targeted therapy.

Guest
Stephen Liu
Stephen Liu

MD

Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Xiuning Le
Xiuning Le

MD, PhD

Associate Professor in the Department of Thoracic and Head and Neck Medical Oncology
University of Texas MD Anderson Cancer Center
Hidehito Horinouchi
Hidehito Horinouchi

MD, PhD

Assistant Chief of the Department of Thoracic Oncology
National Cancer Center Hospital